Disrupting mitochondrial Ca2+ homeostasis causes tumor-selective TRAIL sensitization through mitochondrial network abnormalities

Ohshima,Yohei; Takata,Natsuhiko; Suzuki-Karasaki,Miki; Yoshida,Yukihiro; Tokuhashi,Yasuaki; Suzuki-Karasaki,Yoshihiro

doi:10.3892/ijo.2017.4096

Disrupting mitochondrial Ca2+ homeostasis causes tumor-selective TRAIL sensitization through mitochondrial network abnormalities

Authors:
- Yohei Ohshima
- Natsuhiko Takata
- Miki Suzuki-Karasaki
- Yukihiro Yoshida
- Yasuaki Tokuhashi
- Yoshihiro Suzuki-Karasaki
View Affiliations

Affiliations: Department of Orthopedic Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan, Plasma ChemiBio Laboratory, Nasushiobara, Tochigi 329-2813, Japan
Published online on: August 11, 2017 https://doi.org/10.3892/ijo.2017.4096
Pages: 1146-1158

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has emerged as a promising anticancer agent with high tumor-selective cytotoxicity. The congenital and acquired resistance of some cancer types including malignant melanoma and osteosarcoma impede the current TRAIL therapy of these cancers. Since fine tuning of the intracellular Ca2+ level is essential for cell function and survival, Ca2+ dynamics could be a promising target for cancer treatment. Recently, we demonstrated that mitochondrial Ca2+ removal increased TRAIL efficacy toward malignant melanoma and osteosarcoma cells. Here we report that mitochondrial Ca2+ overload leads to tumor-selective sensitization to TRAIL cytotoxicity. Treatment with the mitochondrial Na+/Ca2+ exchanger inhibitor CGP-37157 and oxidative phosphorylation inhibitor antimycin A and FCCP resulted in a rapid and persistent mitochondrial Ca2+ rise. These agents also increased TRAIL sensitivity in a tumor-selective manner with a switching from apoptosis to a nonapoptotic cell death. Moreover, we found that mitochondrial Ca2+ overload led to increased mitochondrial fragmentation, while mitochondrial Ca2+ removal resulted in mitochondrial hyperfusion. Regardless of their reciprocal actions on the mitochondrial dynamics, both interventions commonly exacerbated TRAIL-induced mitochondrial network abnormalities. These results expand our previous study and suggest that an appropriate level of mitochondrial Ca2+ is essential for maintaining the mitochondrial dynamics and the survival of these cells. Thus, disturbing mitochondrial Ca2+ homeostasis may serve as a promising approach to overcome the TRAIL resistance of these cancers with minimally compromising the tumor-selectivity.

View Figures

View References

1	Almasan A and Ashkenazi A: Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14:337–348. 2003. View Article : Google Scholar : PubMed/NCBI
2	Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 8:782–798. 2008. View Article : Google Scholar : PubMed/NCBI
3	Wang S: The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene. 27:6207–6215. 2008. View Article : Google Scholar : PubMed/NCBI
4	Gonzalvez F and Ashkenazi A: New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 29:4752–4765. 2010. View Article : Google Scholar : PubMed/NCBI
5	Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ and Ashkenazi A: Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 12:611–620. 2000. View Article : Google Scholar : PubMed/NCBI
6	LeBlanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10:66–75. 2003. View Article : Google Scholar : PubMed/NCBI
7	Herrero-Martín G, Høyer-Hansen M, García-García C, Fumarola C, Farkas T, López-Rivas A and Jäättelä M: TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 28:677–685. 2009. View Article : Google Scholar : PubMed/NCBI
8	He W, Wang Q, Xu J, Xu X, Padilla MT, Ren G, Gou X and Lin Y: Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation. Autophagy. 8:1811–1821. 2012. View Article : Google Scholar : PubMed/NCBI
9	Jouan-Lanhouet S, Arshad MI, Piquet-Pellorce C, Martin-Chouly C, Le Moigne-Muller G, Van Herreweghe F, Takahashi N, Sergent O, Lagadic-Gossmann D, Vandenabeele P, et al: TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ. 19:2003–2014. 2012. View Article : Google Scholar : PubMed/NCBI
10	Sosna J, Philipp S, Fuchslocher Chico J, Saggau C, Fritsch J, Föll A, Plenge J, Arenz C, Pinkert T, Kalthoff H, et al: Differences and similarities in TRAIL- and tumor necrosis factor-mediated necroptotic signaling in cancer cells. Mol Cell Biol. 36:2626–2644. 2016. View Article : Google Scholar : PubMed/NCBI
11	Ivanov VN, Bhoumik A and Ronai Z: Death receptors and melanoma resistance to apoptosis. Oncogene. 22:3152–3161. 2003. View Article : Google Scholar : PubMed/NCBI
12	Dyer MJ, MacFarlane M and Cohen GM: Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol. 25(25): 4505–4506. 2007. View Article : Google Scholar : PubMed/NCBI
13	Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A and Ford HL: On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene. 32:1341–1350. 2013. View Article : Google Scholar
14	Guiho R, Biteau K, Heymann D and Redini F: TRAIL-based therapy in pediatric bone tumors: How to overcome resistance. Future Oncol. 11:535–542. 2015. View Article : Google Scholar : PubMed/NCBI
15	de Miguel D, Lemke J, Anel A, Walczak H and Martinez-Lostao L: Onto better TRAILs for cancer treatment. Cell Death Differ. 23:733–747. 2016. View Article : Google Scholar : PubMed/NCBI
16	Elustondo PA, Nichols M, Robertson GS and Pavlov EV: Mitochondrial Ca(2+) uptake pathways. J Bioenerg Biomembr. 49:113–119. 2017. View Article : Google Scholar
17	Bonora M, Wieckowski MR, Chinopoulos C, Kepp O, Kroemer G, Galluzzi L and Pinton P: Molecular mechanisms of cell death: Central implication of ATP synthase in mitochondrial permeability transition. Oncogene. 34:1475–1486. 2015. View Article : Google Scholar
18	Izzo V, Bravo-San Pedro JM, Sica V, Kroemer G and Galluzzi L: Mitochondrial permeability transition: New findings and persisting uncertainties. Trends Cell Biol. 26:655–667. 2016. View Article : Google Scholar : PubMed/NCBI
19	Galluzzi L, Bravo-San Pedro JM, Kepp O and Kroemer G: Regulated cell death and adaptive stress responses. Cell Mol Life Sci. 73:2405–2410. 2016. View Article : Google Scholar : PubMed/NCBI
20	Orrenius S, Gogvadze V and Zhivotovsky B: Calcium and mitochondria in the regulation of cell death. Biochem Biophys Res Commun. 460:72–81. 2015. View Article : Google Scholar : PubMed/NCBI
21	Danese A, Patergnani S, Bonora M, Wieckowski MR, Previati M, Giorgi C and Pinton P: Calcium regulates cell death in cancer: Roles of the mitochondria and mitochondria-associated membranes (MAMs). Biochim Biophys Acta. 1858:615–627. 2017. View Article : Google Scholar : PubMed/NCBI
22	Marchi S and Pinton P: Alterations of calcium homeostasis in cancer cells. Curr Opin Pharmacol. 29:1–6. 2016. View Article : Google Scholar : PubMed/NCBI
23	Monteith GR, Prevarskaya N and Roberts-Thomson SJ: The calcium-cancer signalling nexus. Nat Rev Cancer. 17:367–380. 2017. View Article : Google Scholar : PubMed/NCBI
24	Takata N, Ohshima Y, Suzuki-Karasaki M, Yoshida Y, Tokuhashi Y and Suzuki-Karasaki Y: Mitochondrial Ca²⁺ removal amplifies TRAIL cytotoxicity toward apoptosis-resistant tumor cells via promotion of multiple cell death modalities. Int J Oncol. 51:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
25	Elgass K, Pakay J, Ryan MT and Palmer CS: Recent advances into the understanding of mitochondrial fission. Biochim Biophys Acta. 1833:150–161. 2013. View Article : Google Scholar
26	Chang CR and Blackstone C: Dynamic regulation of mitochondrial fission through modification of the dynamin-related protein Drp1. Ann NY Acad Sci. 1201:34–39. 2010. View Article : Google Scholar : PubMed/NCBI
27	Senft D and Ronai ZA: Regulators of mitochondrial dynamics in cancer. Curr Opin Cell Biol. 39:43–52. 2016. View Article : Google Scholar : PubMed/NCBI
28	Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, Smith CL and Youle RJ: The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell. 1:515–525. 2001. View Article : Google Scholar : PubMed/NCBI
29	Lee YJ, Jeong SY, Karbowski M, Smith CL and Youle RJ: Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. Mol Biol Cell. 15:5001–5011. 2004. View Article : Google Scholar : PubMed/NCBI
30	Estaquier J and Arnoult D: Inhibiting Drp1-mediated mitochondrial fission selectively prevents the release of cytochrome c during apoptosis. Cell Death Differ. 14:1086–1094. 2007. View Article : Google Scholar : PubMed/NCBI
31	Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, Salgia R, Husain AN, Wietholt C and Archer SL: Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J. 26:2175–2186. 2012. View Article : Google Scholar : PubMed/NCBI
32	Westrate LM, Sayfie AD, Burgenske DM and MacKeigan JP: Persistent mitochondrial hyperfusion promotes G2/M accumulation and caspase-dependent cell death. PLoS One. 9:e919112014. View Article : Google Scholar : PubMed/NCBI
33	Akita M, Suzuki-Karasaki M, Fujiwara K, Nakagawa C, Soma M, Yoshida Y, Ochiai T, Tokuhashi Y and Suzuki-Karasaki Y: Mitochondrial division inhibitor-1 induces mitochondrial hyperfusion and sensitizes human cancer cells to TRAIL-induced apoptosis. Int J Oncol. 45:1901–1912. 2014. View Article : Google Scholar : PubMed/NCBI
34	Suzuki-Karasaki Y, Fujiwara K, Saito K, Suzuki-Karasaki M, Ochiai T and Soma M: Distinct effects of TRAIL on the mitochondrial network in human cancer cells and normal cells: Role of plasma membrane depolarization. Oncotarget. 6:21572–21588. 2015. View Article : Google Scholar : PubMed/NCBI
35	Nita II, Hershfinkel M, Kantor C, Rutter GA, Lewis EC and Sekler I: Pancreatic β-cell Na⁺ channels control global Ca²⁺ signaling and oxidative metabolism by inducing Na⁺ and Ca²⁺ responses that are propagated into mitochondria. FASEB J. 28:3301–3312. 2014. View Article : Google Scholar : PubMed/NCBI
36	Ruiz A, Alberdi E and Matute C: CGP37157, an inhibitor of the mitochondrial Na+/Ca²⁺ exchanger, protects neurons from excitotoxicity by blocking voltage-gated Ca²⁺ channels. Cell Death Dis. 5:e11562014. View Article : Google Scholar
37	Ben-Hail D, Palty R and Shoshan-Barmatz V: Measurement of mitochondrial Ca²⁺ transport mediated by three transport proteins: VDAC1, the Na⁺/Ca²⁺ exchanger, and the Ca²⁺ uniporter. Cold Spring Harb Protoc. 2014:161–166. 2014.PubMed/NCBI
38	Izeradjene K, Douglas L, Tillman DM, Delaney AB and Houghton JA: Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Cancer Res. 65:7436–7445. 2005. View Article : Google Scholar : PubMed/NCBI
39	Inoue T and Suzuki-Karasaki Y: Mitochondrial superoxide mediates mitochondrial and endoplasmic reticulum dysfunctions in TRAIL-induced apoptosis in Jurkat cells. Free Radic Biol Med. 61:273–284. 2013. View Article : Google Scholar : PubMed/NCBI
40	Suzuki-Karasaki M, Ochiai T and Suzuki-Karasaki Y: Crosstalk between mitochondrial ROS and depolarization in the potentiation of TRAIL-induced apoptosis in human tumor cells. Int J Oncol. 44:616–628. 2014. View Article : Google Scholar
41	Bernardi P and von Stockum S: The permeability transition pore as a Ca(2+) release channel: New answers to an old question. Cell Calcium. 52:22–27. 2012. View Article : Google Scholar : PubMed/NCBI
42	Gutiérrez-Aguilar M and Baines CP: Structural mechanisms of cyclophilin D-dependent control of the mitochondrial permeability transition pore. Biochim Biophys Acta. 1850:2041–2047. 2015. View Article : Google Scholar :
43	Kaddour-Djebbar I, Lakshmikanthan V, Shirley RB, Ma Y, Lewis RW and Kumar MV: Therapeutic advantage of combining calcium channel blockers and TRAIL in prostate cancer. Mol Cancer Ther. 5:1958–1966. 2006. View Article : Google Scholar : PubMed/NCBI
44	Kaddour-Djebbar I, Choudhary V, Brooks C, Ghazaly T, Lakshmikanthan V, Dong Z and Kumar MV: Specific mitochondrial calcium overload induces mitochondrial fission in prostate cancer cells. Int J Oncol. 36:1437–1444. 2010.PubMed/NCBI
45	Han J, Hou W, Goldstein LA, Lu C, Stolz DB, Yin XM and Rabinowich H: Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem. 283:19665–19677. 2008. View Article : Google Scholar : PubMed/NCBI
46	Hou W, Han J, Lu C, Goldstein LA and Rabinowich H: Enhancement of tumor-TRAIL susceptibility by modulation of autophagy. Autophagy. 4:940–943. 2008. View Article : Google Scholar : PubMed/NCBI
47	Nikoletopoulou V, Markaki M, Palikaras K and Tavernarakis N: Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta. 1833:3448–3459. 2013. View Article : Google Scholar : PubMed/NCBI
48	Goodall ML, Fitzwalter BE, Zahedi S, Wu M, Rodriguez D, Mulcahy-Levy JM, Green DR, Morgan M, Cramer SD and Thorburn A: The autophagy machinery controls cell death switching between apoptosis and necroptosis. Dev Cell. 37:337–349. 2016. View Article : Google Scholar : PubMed/NCBI
49	Haga N, Fujita N and Tsuruo T: Mitochondrial aggregation precedes cytochrome c release from mitochondria during apoptosis. Oncogene. 22:5579–5585. 2003. View Article : Google Scholar : PubMed/NCBI
50	Haga N, Fujita N and Tsuruo T: Involvement of mitochondrial aggregation in arsenic trioxide (As₂O₃)-induced apoptosis in human glioblastoma cells. Cancer Sci. 96:825–833. 2005. View Article : Google Scholar : PubMed/NCBI